Summary: Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio. The growth was driven by a 17% increase in Xywav sales and a 100% increase in high-sodium oxybate authorized generic (AG) royalties, … [Read more...]
Impact of Philips’ Portfolio Changes: Earn Continuing Education
Terms for CSTE Qualification The Board of Registered Polysomnographic Technologists (BRPT) designates this educational activity–Sleep Review’s April, May, & June/July 2024 Digital Edition series—for a maximum of 1.5 Continuing Sleep Technology Education (CSTE) credits. … [Read more...]
Harmony’s Q1 Report Shows Growth in Sleep/Wake Portfolio
Summary: Harmony Biosciences Holdings Inc described initially-quarter effects, showcasing development in its rest/wake portfolio. Key highlights consist of a rise in sufferers on Wakix, enhancements in the idiopathic hypersomnia program with designs for pitolisant, and positive … [Read more...]